Abstract: A a triple agonist having activities to all of glucagon, GLP-1, and GIP receptors is disclosed. Uses of the triple agonist are disclosed.

Abstract: A long-acting conjugate of a triple agonist which has activities to all of glucagon, GLP-1, and GIP receptors and uses thereof.

Abstract: The present invention relates to an insulin analog that has reduced insulin receptor binding affinity for the purpose of increasing the blood half-life of insulin, and long-acting insulin, a conjugate, and a method of preparing long-acting insulin using the same.

Abstract: The present invention relates to a triple agonist having activities to all of glucagon, GLP-1, and GIP receptors and uses thereof.

Abstract: The present invention relates to a long-acting conjugate of a triple agonist having activities to all of glucagon, GLP-1, and GIP receptors and uses thereof.

Abstract: An insulin analog with an improved in vitro effect compared with native insulin, a nucleic acid encoding the same, an expression vector including the nucleic acid, a transformant introduced with the expression vector, a method of producing the insulin analog from the transformant, a pharmaceutical composition for treating diabetes containing the insulin analog as an active ingredient, and a method for treating diabetes using the insulin analog or the pharmaceutical composition.

Abstract: Insulin analog with an improved in vitro effect compared with native insulin, a nucleic acid encoding the same, an expression vector including the nucleic acid, a transformant introduced with the expression vector, a method of producing the insulin analog from the transformant, a pharmaceutical composition for treating diabetes containing the insulin analog as an active ingredient, and a method for treating diabetes using the insulin analog or the pharmaceutical composition are described.

Abstract: The present invention relates to an insulin analog that has reduced insulin receptor binding affinity for the purpose of increasing the blood half-life of insulin, and long-acting insulin, a conjugate, and a method of preparing long-acting insulin using the same.

Abstract: The present invention relates to a novel insulin analog, and more specifically, to an insulin analog with an improved in vitro effect compared with native insulin, a nucleic acid encoding the same, an expression vector including the nucleic acid, a transformant introduced with the expression vector, a method of producing the insulin analog from the transformant, a pharmaceutical composition for treating diabetes containing the insulin analog as an active ingredient, and a method for treating diabetes using the insulin analog or the pharmaceutical composition.

Abstract: Disclosed is a method of culturing E. coli cells for high density, comprising a cell growth step and an expression induction step by which a maximum of cell mass can be obtained with the concomitant maximum expression of a recombinant protein. E. coli transformed to produce a recombinant protein of interest can be grown at a high concentration using the culturing method of the present invention. Therefore, the method increases the productivity of cells as well as the production yield of the recombinant protein, and can be widely applied to the effective production of recombinant proteins.

Abstract: The present invention relates to a transformant prepared by introducing an expression vector comprising a polynucleotide encoding for a human immunoglobulin Fc fragment into Pichia sp. yeast, a method for producing an immunoglobulin Fc fragment comprising culturing the transformant, and recovering the immunoglobulin Fc fragment from the culture, and an immunoglobulin Fc fragment, prepared by the above method for use as a drug carrier. The transformant is suggested as a solution to the problems associated with the use of E. coli or animal cells as hosts for producing immunoglobulin Fc fragments useful as drug carriers, so that it can find various applications in the effective and economical production of drugs.

Abstract: The present invention relates to a transformant prepared by introducing an expression vector comprising a polynucleotide encoding for a human immunoglobulin Fc fragment into Pichia sp. yeast, a method for producing an immunoglobulin Fc fragment comprising culturing the transformant, and recovering the immunoglobulin Fc fragment from the culture, and an immunoglobulin Fc fragment, prepared by the above method for use as a drug carrier. The transformant is suggested as a solution to the problems associated with the use of E. coli or animal cells as hosts for producing immunoglobulin Fc fragments useful as drug carriers, so that it can find various applications in the effective and economical production of drugs.

Abstract: Disclosed is a method of culturing E. coli cells for high density, comprising a cell growth step and an expression induction step by which a maximum of cell mass can be obtained with the concomitant maximum expression of a recombinant protein. E. coli transformed to produce a recombinant protein of interest can be grown at a high concentration using the culturing method of the present invention. Therefore, the method increases the productivity of cells as well as the production yield of the recombinant protein, and can be widely applied to the effective production of recombinant proteins.

Abstract: The present invention relates to immunoglobulin Fc variants having an increased binding affinity for FcRn, which is characterized by including one or more amino acid modifications selected from the group consisting of 307S, 308F, 380S, 380A, 428L, 429K, 430S, 433K and 434S (this numbering is according to the EU index) in the constant region of a native immunoglobulin Fc fragment. Owing to the high binding affinity for FcRn, the immunoglobulin Fc variants according to the present invention show more prolonged in vivo half-life, and thus can be used for the preparation of a long-acting formulation of protein drugs.